Literature DB >> 11095612

Growth factors and collagen distribution in vernal keratoconjunctivitis.

A Leonardi1, P Brun, M Tavolato, G Abatangelo, M Plebani, A G Secchi.   

Abstract

PURPOSE: To study the extracellular composition of giant papillae in vernal keratoconjunctivitis (VKC) and the expression of growth factors that may stimulate fibrosis.
METHODS: Upper conjunctival specimens were obtained by biopsy in 9 patients affected by active tarsal VKC (14 eyes) and 10 normal control subjects. Immunohistochemistry was performed on tissue sections using monoclonal antibodies (mAbs) for collagens I, III, and VII; tumor necrosis factor (TNF)-alpha; transforming growth factor (TGF)-ss1; basic fibroblast growth factor (bFGF); and platelet-derived growth factor (PDGF). The mAbs anti-tryptase, anti-CD4, anti-CD68, and anti-EG2 were used as markers for mast cells, T-helper lymphocytes, macrophages, and eosinophils, respectively. Immunofluorescent double-staining for growth factors and cell markers was performed in VKC tissues.
RESULTS: Immunostaining was highly positive for collagens I, III, and VII in the subepithelium of VKC conjunctiva. Image analysis showed a significant increase of staining per tissue area for both collagens I and VII and increased basal membrane length. The number of cells positive for TNF-alpha, TGF-ss, bFGF, or PDGF was significantly higher in VKC tissue than in control samples. Double staining showed that eosinophils and macrophages were the main sources of PDGF and that FGF was expressed by 46% of mast cells. Significant PDGF and FGF staining was observed in the conjunctival epithelium and vascular endothelium of all VKC tissues.
CONCLUSIONS: In giant papillae of VKC, the extracellular matrix is characterized by overproduction of collagens. Expression of growth factors in the conjunctiva by resident cells (mast cells, epithelial cells, endothelial cells) and inflammatory cells (macrophages, eosinophils) may contribute to papillae formation and fibrosis evolution in chronic ocular allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095612

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

Review 1.  [Ocular allergies].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

Review 2.  Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis.

Authors:  Pakit Vichyanond; Panida Kosrirukvongs
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

Review 3.  Linking immune responses with fibrosis in allergic eye disease.

Authors:  Sarah B Dale; Daniel R Saban
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-10

Review 4.  Allergy and the eye.

Authors:  A Leonardi; L Motterle; M Bortolotti
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

Review 5.  The central role of conjunctival mast cells in the pathogenesis of ocular allergy.

Authors:  Andrea Leonardi
Journal:  Curr Allergy Asthma Rep       Date:  2002-07       Impact factor: 4.919

6.  Quiescent and Active Tear Protein Profiles to Predict Vernal Keratoconjunctivitis Reactivation.

Authors:  Alessandra Micera; Antonio Di Zazzo; Graziana Esposito; Roberto Sgrulletta; Virginia L Calder; Stefano Bonini
Journal:  Biomed Res Int       Date:  2016-02-17       Impact factor: 3.411

7.  Nerve growth factor has a modulatory role on human primary fibroblast cultures derived from vernal keratoconjunctivitis-affected conjunctiva.

Authors:  Alessandra Micera; Alessandro Lambiase; Barbara Stampachiacchiere; Roberto Sgrulletta; Eduardo Maria Normando; Sergio Bonini; Stefano Bonini
Journal:  Mol Vis       Date:  2007-06-21       Impact factor: 2.367

8.  Overexpression of TGF-beta by infiltrated granulocytes correlates with the expression of collagen mRNA in pancreatic cancer.

Authors:  Y Aoyagi; T Oda; T Kinoshita; C Nakahashi; T Hasebe; N Ohkohchi; A Ochiai
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.